ORIC Pharmaceuticals Doses First Patients Across Expansion Arms in the P-Ib Study of ORIC-114 for the Treatment of Mutated NSCLC
Shots:
- The P-Ib dose escalation part of the study assessed the safety, tolerability, PK profile, provisional RP2D & preliminary antitumor activity of ORIC-114 for treating solid tumors associated with EGFR & HER2 exon 20 mutations as well as HER2 amplifications
- ORIC concluded the dose escalation part of the study and selected 80mg & 120mg QD as provisional RP2D to be further evaluated for final RP2D in the P-Ib dose expansion part assessing ORIC-114’s safety & efficacy in mutated NSCLC patients incl. EGFR exon 20, HER2 exon 20 & EGFR atypical mutations
- Furthermore, the company has commenced an extension arm to investigate ORIC-114 for 1L, treatment-naïve EGFR exon 20 NSCLC treatment. Updated P-Ib data is anticipated in H1’25
Ref: ORIC Pharmaceuticals | Image: ORIC Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
